Acute painful lumbosacral paresthesia after intrathecal rituximab

Journal of Neurology

Volumn 259, Issue 3, 2012, Pages 559-561

  Bromberg, J E C ^a   Doorduijn, J K ^a   Baars, J W ^b   Van Imhoff, G W ^c   Enting, R ^c   Van Den Bent, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; METHOTREXATE; RITUXIMAB;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEASIBILITY STUDY; HUMAN; LETTER; LUMBOSACRAL PARESTHESIA; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SPINAL; MALE; MIDDLE AGED; PARESTHESIA;

EID: 84862520252     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6190-y     Document Type: Letter

References (13)

1. Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SU, Tjak RV, Charvat MV, Kluin-Nelemans JC (1997) Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 54:854-859 (Pubitemid 27306622)
2. Recht L, Straus DJ, Cirrincione C, Thaler HT, Posner JB (1988) Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am J Med 84:425-435
3. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 ? Bcell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116
4. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
5. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101:466-468 (Pubitemid 36077565)
6. Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, Deangelis LM, Abrey LE (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730-4735 (Pubitemid 350086474)
7. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25:1350-1356 (Pubitemid 46706881)
8. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A (2004) Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89:753-754 (Pubitemid 38828486)
9. Antonini G, Cox MC, Montefusco E, Ferrari A, Conte E, Morino S, Latino P, Trasimeni G, Monarca B (2007) Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 81:197-199 (Pubitemid 44963979)
10. Nelson RW, Frank JT (1981) Intrathecal methotrexate-induced neurotoxicities. Am J Hosp Pharm 38:65-68 (Pubitemid 11180917)
11. Kim S, Chatelut E, Kim JC, Howell SB, Cates C, Kormanik PA, Chamberlain MC (1993) Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11:2186-2193 (Pubitemid 23332256)
12. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA (2007) Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109:3214-3218 (Pubitemid 46572506)
13. Ostermann K, Pels H, Kowoll A, Kuhnhenn J, Schlegel U (2011) Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol 103:635-640